Fifth Third Wealth Advisors LLC Acquires 100 Shares of Humana Inc. $HUM

Fifth Third Wealth Advisors LLC boosted its holdings in Humana Inc. (NYSE:HUM) by 8.1% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 1,337 shares of the insurance provider’s stock after purchasing an additional 100 shares during the period. Fifth Third Wealth Advisors LLC’s holdings in Humana were worth $327,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Cary Street Partners Investment Advisory LLC lifted its stake in Humana by 63.9% in the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock worth $31,000 after purchasing an additional 46 shares during the last quarter. Garde Capital Inc. bought a new stake in Humana in the first quarter worth $36,000. Zions Bancorporation National Association UT bought a new stake in Humana in the first quarter worth $37,000. Ransom Advisory Ltd bought a new stake in Humana in the first quarter worth $66,000. Finally, Rakuten Securities Inc. lifted its stake in Humana by 50.0% in the first quarter. Rakuten Securities Inc. now owns 300 shares of the insurance provider’s stock worth $79,000 after purchasing an additional 100 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Humana Price Performance

Shares of NYSE HUM opened at $270.84 on Tuesday. Humana Inc. has a 1 year low of $206.87 and a 1 year high of $315.35. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. The company’s 50-day moving average is $279.92 and its 200 day moving average is $258.09. The stock has a market capitalization of $32.57 billion, a P/E ratio of 20.79, a P/E/G ratio of 1.64 and a beta of 0.42.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The company had revenue of $32.39 billion for the quarter, compared to analysts’ expectations of $31.85 billion. During the same quarter in the prior year, the firm earned $6.96 EPS. Humana’s quarterly revenue was up 9.6% compared to the same quarter last year. Humana has set its FY 2025 guidance at 17.000- EPS. On average, sell-side analysts expect that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $3.54 annualized dividend and a yield of 1.3%. Humana’s payout ratio is presently 27.17%.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Robert W. Baird decreased their price objective on shares of Humana from $300.00 to $297.00 and set a “neutral” rating on the stock in a research report on Friday, July 25th. Barclays decreased their price objective on shares of Humana from $315.00 to $245.00 and set an “equal weight” rating on the stock in a research report on Friday, October 3rd. Wolfe Research boosted their price objective on shares of Humana from $283.00 to $313.00 and gave the company an “outperform” rating in a research report on Monday, October 6th. Evercore ISI assumed coverage on shares of Humana in a research report on Monday, September 22nd. They issued an “in-line” rating and a $295.00 price objective on the stock. Finally, Guggenheim restated a “buy” rating on shares of Humana in a research report on Friday, October 3rd. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $298.83.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.